Skip to main content
TipRanks
Go Ultimate75% OFF

OncoTherapy Science (4564) AI Stock Analysis

2 Followers
JP:4564

OncoTherapy Science

(TSE/TYO:4564)

Select Model
Rating:26Underperform
Price Target:JPY 13.00â–¼(-13.33% Downside)
Action:reiterated
Date:11/12/26

The score is driven primarily by severely weak financials: chronic unprofitability, losses larger than revenue, negative gross margins, and roughly ¥1B of annual cash burn that forces reliance on dilutive capital raises. A debt-free balance sheet is the only meaningful financial positive. Technicals reinforce the caution, with the price below all major moving averages and a negative MACD, though an oversold stochastic hints at possible short-term stabilization. Valuation adds no support given a negative P/E and no dividend. This remains a high-risk, speculative biotech whose outcome hinges on pipeline success and continued access to funding.

Positive Factors
Debt-Free Balance SheetA debt-free balance sheet gives OncoTherapy Science greater financial flexibility while it funds oncology research and development. The increased equity cushion can help absorb operating volatility and reduces the immediate burden of interest expense or debt refinancing as the company pursues future candidates.
Negative Factors
Revenue DeclineThe recent revenue decline and historical volatility indicate that commercial or development-related income has not yet established a dependable growth trajectory. An unstable top line makes it harder to spread fixed research costs, plan investment confidently, or demonstrate improving operating leverage over the next several quarters.

OncoTherapy Science (4564) vs. iShares MSCI Japan ETF (EWJ)

-40%-20%0%20%40%60%JP:4564-25.00%EWJ+11.03%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.12B
Dividend Yield
―
Average Volume (3M)
182.35M
Price to Earnings (P/E)
-6.5
Beta (1Y)
1.02
Revenue Growth
-25.56%
EPS Growth
17.01%
Country
Japan
Employees
46
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

OncoTherapy Science Business Overview & Revenue Model

Company Description

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound th...

OncoTherapy Science Financial Statement Overview

Summary

Financials are very weak. The company is persistently unprofitable, with net losses exceeding revenue (FY2026 forecast: ¥911M loss on ¥809M of revenue) and negative gross and EBIT margins (Income Statement score 10). Cash flow is the biggest concern, with operating and free cash flow deeply negative every year and roughly ¥1B of annual cash burn projected for FY2026 (Cash Flow score 8). The balance sheet is the relative bright spot — minimal to zero debt — but equity has been eroded by losses and only rebuilt through capital raises that dilute shareholders, with deeply negative returns on equity (Balance Sheet score 35). Survival depends on continued external financing and pipeline success.

Income Statement

10Very Negative

Balance Sheet

35Negative

Cash Flow

8Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2022Mar 2021
Income Statement
Total Revenue749.75M808.53M750.05M610.12M1.13B332.48M
Gross Profit-12.76M13.96M-12.76M-177.72M41.69M19.54M
EBITDA-126.67M-810.38M-14.92M-165.50M-1.10B-1.59B
Net Income-815.05M-910.64M-815.28M-1.29B-1.12B-1.56B
Balance Sheet
Total Assets1.16B2.36B1.16B867.27M1.51B3.37B
Cash, Cash Equivalents and Short-Term Investments833.88M2.09B833.88M527.66M1.12B2.90B
Total Debt51.07M051.07M106.85M00
Total Liabilities426.09M217.37M426.09M513.61M656.27M291.28M
Stockholders Equity729.11M2.14B729.11M353.67M855.17M3.08B
Cash Flow
Free Cash Flow0-984.97M-815.30M-1.23B-800.29M-1.81B
Operating Cash Flow0-922.75M-815.02M-1.23B-794.90M-1.76B
Investing Cash Flow0-63.22M-279.00K-33.35M-20.32M-52.23M
Financing Cash Flow02.24B1.12B671.37M95.95M0

OncoTherapy Science Technical Analysis

Technical Analysis SentimentNegative
Last Price15.00

Price Trends

50DMA19.00Negative
100DMA19.54Negative
200DMA20.64Negative

Market Momentum

MACD-1.03Positive
RSI30.84Neutral
STOCH25.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4564, the sentiment is Negative. The current price of 15.00 is below the 20-day moving average (MA) of 16.65, below the 50-day MA of 19.00, and below the 200-day MA of 20.64, indicating a bearish trend. The MACD of -1.03 indicates Positive momentum. The RSI at 30.84 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4564.

OncoTherapy Science Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4564 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4565JP:456563NeutralJPY 154.11B-26.91-8.51%―23.72%12.48%
JP:4579JP:457962NeutralJPY 18.95B42.63――31.84%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4588JP:458851NeutralJPY 208.84B-122.94――1748.97%35.11%
JP:4587JP:458748NeutralJPY 144.11B-48.17-5.85%―14.25%50.07%
JP:4571JP:457141NeutralJPY 6.37B-4.20-39.57%―48.92%-46.91%
JP:4564JP:456426UnderperformJPY 6.12B-6.52-42.81%―-25.56%17.01%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%JP:4564JP:4587JP:4565JP:4571JP:4579JP:4588Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4564 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4564OncoTherapy Science, Inc.15.00-6.00-28.57%
JP:4587Peptidream 1110.00-516.00-31.73%
JP:4565Sosei Group Corporation1664.00802.0093.04%
JP:4571NanoCarrier Co., Ltd.70.00-74.00-51.39%
JP:4579RaQualia Pharma Inc.728.0039.005.66%
JP:4588Oncolys BioPharma, Inc.7070.006105.00632.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026